Investigational drugs for immune thrombocytopenia

References

• Provan D, Arnold DM, Bussel JB, et al., Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 3(22): 3780–3817. 2019
   PubMed Web of Science ®Google Scholar
• Moulis G, Palmaro A, Montastruc JL, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–3315.
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al., American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 3(23): 3829–3866. 2019
   PubMed Web of Science ®Google Scholar
• Singh A, Uzun G, Bakchoul T. Primary immune thrombocytopenia: novel insights into pathophysiology and disease management. J Clin Med. 2021;10(4):789.
   PubMedGoogle Scholar
• Semple JW, Provan D. The immunopathogenesis of immune thrombocytopenia: t cells still take center-stage. Curr Opin Hematol. 2012;19(5):357–362
   PubMed Web of Science ®Google Scholar
• Semple JW, Rebetz J, Maouia A, et al. An update on the pathophysiology of immune thrombocytopenia. Curr Opin Hematol. 2020;27(6):423–429.
   PubMed Web of Science ®Google Scholar
• Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022;76:103820.
   Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186.
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549–2554
   PubMed Web of Science ®Google Scholar
• Boyle S, White RH, Brunson A, et al. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121(23):4782–4790.
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) world impact survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199–207.
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) world impact survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188–198.
   PubMed Web of Science ®Google Scholar
• Costanzo G, Cordeddu W, Chessa L, et al. COVID-19: considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic. World J Clin Cases. 2021;9(20):5352–5357.
   PubMedGoogle Scholar
• Pavord S, Thachil J, Hunt BJ, et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2020;189(6):1038–1043.
   PubMed Web of Science ®Google Scholar
• Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992;89(12):5640–5644.
   PubMed Web of Science ®Google Scholar
• de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369(6481):533–538.
   PubMed Web of Science ®Google Scholar
• Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369(6481):565–568
   PubMed Web of Science ®Google Scholar
• Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77(7):1117–1124.
   PubMed Web of Science ®Google Scholar
• Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem. 1995;118(1):229–236
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994;91(23):11104–11108
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241–3248.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23.
   PubMed Web of Science ®Google Scholar
• Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood. 1995;85(2):391–401.
   PubMed Web of Science ®Google Scholar
• Zhang J, Freyer D, Rung O, et al. Inflammation stimulates thrombopoietin (Tpo) expression in rat brain-derived microvascular endothelial cells, but suppresses Tpo in astrocytes and microglia. J Interferon Cytokine Res. 2010;30(7):465–469.
   PubMedGoogle Scholar
• Kaushansky K, Broudy VC, Grossmann A, et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest. 1995;96(3):1683–1687.
   PubMedGoogle Scholar
• Ikeda Y, Miyakawa Y. Development of thrombopoietin receptor agonists for clinical use. J Thromb Haemost. 2009;7:1239–1244.
   PubMedGoogle Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–3894.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen L, Zhang F, et al. First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. J Thromb Haemost. 2020;18(11):3053–3060.
   PubMedGoogle Scholar
• Syed YY. Hetrombopag: first Approval. Drugs. 2021;81(13):1581–1585.
   PubMed Web of Science ®Google Scholar
• Mei H, Liu X, Li Y, et al. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021;14(1):37.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Tateishi R, Hiroi S, et al. Effects of lusutrombopag on post-invasive procedural bleeding in thrombocytopenic patients with chronic liver disease. Adv Ther. 2022;39(1):379–390.
   PubMed Web of Science ®Google Scholar
• Cooper N, Hill QA, Grainger J, et al. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified delphi panel. Acta Haematol. 2021;144(4):418–426.
   PubMedGoogle Scholar
• Cervinek L, Mayer J, Doubek M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol. 2015;102(1):7–11.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez TJ, Pascual C, Alvarez-Roman MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40–3.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, et al., Thrombopoietin receptor agonists: ten years later. Haematologica. 104(6): 1112–1123. 2019
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Jiang D, Gernsheimer TB, et al. Durability of platelet response when switching from eltrombopag or romiplostim to avatrombopag in immune thrombocytopenia (itp): a multicenter study. Blood. 2021;138(Supplement 1):1015. ASH Congress 2021.; Poster 1015.
   Google Scholar
• Brambell FW, Halliday R, Brierley J, et al. Transference of passive immunity from mother to young. Lancet. 1954;266(6819):964–965.
   PubMedGoogle Scholar
• Brambell FW. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet. 1966;2(7473):1087–1093
   PubMed Web of Science ®Google Scholar
• Rodewald R, Kraehenbuhl JP. Receptor-mediated transport of IgG. J Cell Biol. 1984;99(1 Pt 2):159s–164s.
   PubMedGoogle Scholar
• Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol. 1996;12:181–220.
   Google Scholar
• Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352–1354.
   PubMedGoogle Scholar
• Simister NE, Rees AR. Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol. 1985;15(7):733–738.
   PubMedGoogle Scholar
• Kenniston JA, Taylor BM, Conley GP, et al. Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody. J Biol Chem. 2017;292(42):17449–17460.
   PubMedGoogle Scholar
• Sand KM, Bern M, Nilsen J, et al. Unraveling the interaction between fcrn and albumin: opportunities for design of albumin-based therapeutics. Front Immunol. 2014;5:682.
   PubMed Web of Science ®Google Scholar
• Pyzik M, Sand KMK, Hubbard JJ, et al. The neonatal Fc receptor (FcRn): a misnomer. Front Immunol. 2019;10:1540.
   PubMed Web of Science ®Google Scholar
• Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: function and role in therapeutic intervention. J Allergy Clin Immunol. 2020;146(3):467–478.
   PubMedGoogle Scholar
• Mezo AR, McDonnell KA, Hehir CA, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc Natl Acad Sci U S A. 2008;105(7):2337–2342.
   PubMedGoogle Scholar
• Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9(414):eaan1208.
   PubMed Web of Science ®Google Scholar
• Ling LE, Hillson JL, Tiessen RG, et al. M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin Pharmacol Ther. 2019;105(4):1031–1039.
   PubMed Web of Science ®Google Scholar
• Nixon AE, Chen J, Sexton DJ, et al. Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates. Front Immunol. 2015;6:176.
   PubMedGoogle Scholar
• Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372–4386.
   PubMed Web of Science ®Google Scholar
• van Bilsen K, van Hagen PM, Bastiaans J, et al. The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-alpha. Br J Ophthalmol. 2011;95(6):864–868.
   PubMedGoogle Scholar
• Vidarsson G, Stemerding AM, Stapleton NM, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood. 2006;108(10):3573–3579.
   PubMedGoogle Scholar
• Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–3236.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9978):1653–1661.
   PubMed Web of Science ®Google Scholar
• Robak T, Kaźmierczak M, Jarque I, et al. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Adv. 2020;4(17):4136–4146.
   PubMed Web of Science ®Google Scholar
• Newland AC, Sánchez-González B, Rejtő L, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020;95(2):178–187.
   PubMed Web of Science ®Google Scholar
• Howard JF, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–e2673.
   PubMed Web of Science ®Google Scholar
• Geahlen RL. Syk and pTyr’d: signaling through the B cell antigen receptor. Biochim Biophys Acta. 2009;1793(7):1115–1127.
   PubMed Web of Science ®Google Scholar
• Xue L, Geahlen RL, Tao WA. Identification of direct tyrosine kinase substrates based on protein kinase assay-linked phosphoproteomics. Mol Cell Proteomics. 2013;12(10):2969–2980.
   PubMed Web of Science ®Google Scholar
• Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387–402.
   PubMed Web of Science ®Google Scholar
• Yablonski D, Weiss A. Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. Adv Immunol. 2001; 79:93–128.
   PubMedGoogle Scholar
• LeibundGut-Landmann S, Gross O, Robinson MJ, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol. 2007;8(6):630–638.
   PubMed Web of Science ®Google Scholar
• Cheng AM, Rowley B, Pao W, et al. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378(6554):303–306.
   PubMed Web of Science ®Google Scholar
• Choi OH, Kim JH, Kinet JP. Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor. Nature. 1996;380(6575):634–636.
   PubMedGoogle Scholar
• Darby C, Geahlen RL, Schreiber AD. Stimulation of macrophage Fc gamma RIIIA activates the receptor-associated protein tyrosine kinase Syk and induces phosphorylation of multiple proteins including p95Vav and p62/GAP-associated protein. J Immunol. 1994;152(11):5429–5437.
   PubMedGoogle Scholar
• Reeve JL, Zou W, Liu Y, et al. SLP-76 couples Syk to the osteoclast cytoskeleton. J Immunol. 2009;183(3):1804–1812.
   PubMedGoogle Scholar
• Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591–619.
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev. 2009;228(1):132–148.
   PubMed Web of Science ®Google Scholar
• Sánchez-Mejorada G, Rosales C. Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol. 1998;63(5):521–533.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47.
   PubMed Web of Science ®Google Scholar
• Wu Y, Pan W, Hu X, et al. The prospects for targeting FcR as a novel therapeutic strategy in rheumatoid arthritis. Biochem Pharmacol. 2021;183:114360.
   Google Scholar
• Chakravarty SD, Poulikakos PI, Ivashkiv LB, et al. Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis. Clin Immunol. 2013;148(1):66–78.
   PubMedGoogle Scholar
• Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–930.
   PubMed Web of Science ®Google Scholar
• Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–728.
   PubMed Web of Science ®Google Scholar
• Jongstra-Bilen J, Puig Cano A, Hasija M, et al. Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol. 2008;181(1):288–298.
   PubMed Web of Science ®Google Scholar
• Fiedler K, Sindrilaru A, Terszowski G, et al. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood. 2011;117(4):1329–1339.
   PubMed Web of Science ®Google Scholar
• Volmering S, Block H, Boras M, et al. The neutrophil btk signalosome regulates integrin activation during sterile inflammation. Immunity. 2016;44(1):73–87.
   PubMedGoogle Scholar
• Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.
   PubMedGoogle Scholar
• Hampel PJ, Larson MC, Kabat B, et al. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol. 2018;183(3):421–427.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30(2):346–350.
   PubMed Web of Science ®Google Scholar
• Naylor-Adamson L, Chacko AR, Booth Z, et al. Bruton’s tyrosine kinase inhibitors impair FcγRIIA-driven platelet responses to bacteria in chronic lymphocytic leukemia. Front Immunol. 2021;12:766272.
   PubMedGoogle Scholar
• Smith PF, Krishnarajah J, Nunn PA, et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers. Br J Clin Pharmacol. 2017;83(11):2367–2376.
   PubMed Web of Science ®Google Scholar
• Kuter D, Tzvetkov N, E M, et al. Phase I/II ongoing study of rilzabrutinib, an oral bruton tyrosine kinase inhibitor, in immune thrombocytopenia: extended follow-up and long-term analyses with optimal dose. J Thromb Haemost. 2019;19:OC 72.2.
   Google Scholar
• Langrish CL, Bradshaw JM, Francesco MR, et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease. J Immunol. 2021;206(7):1454–1468.
   PubMedGoogle Scholar
• Kulasekararaj A, Glasmacher A, Liu P, et al. Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria. Eur J Haematol. 2022;108(5):391–402.
   PubMedGoogle Scholar
• Gurnari C, Pagliuca S, Maciejewski JP. Pegcetacoplan versus Eculizumab in PNH. N Engl J Med. 2021;385(18):1725.
   PubMedGoogle Scholar
• Najaoui A, Bakchoul T, Stoy J, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88(2):167–174.
   PubMed Web of Science ®Google Scholar
• Peerschke EI, Andemariam B, Yin W, et al. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol. 2010;148(4):638–645.
   PubMed Web of Science ®Google Scholar
• Cheloff AZ, Kuter DJ, Al-Samkari H. Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features. Res Pract Thromb Haemost. 2020;4(5):807–812.
   PubMed Web of Science ®Google Scholar
• Röth A, Barcellini W, D’Sa S, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021;384(14):1323–1334.
   PubMed Web of Science ®Google Scholar
• Broome CM, Röth A, Kuter DJ, et al. Long-term safety and efficacy of sutimlimab in patients with chronic immune thrombocytopenia. Blood. 2020;136(Supplement 1):14–15.
   Google Scholar
• Kawabe T, Naka T, Yoshida K, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity. 1994;1(3):167–178.
   PubMed Web of Science ®Google Scholar
• Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol. 2009;21(5):257–264.
   PubMedGoogle Scholar
• Howard LM, Miga AJ, Vanderlugt CL, et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest. 1999;103(2):281–290.
   PubMed Web of Science ®Google Scholar
• Im SH, Barchan D, Maiti PK, et al. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol. 2001;166(11):6893–6898.
   PubMed Web of Science ®Google Scholar
• Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.
   Web of Science ®Google Scholar
• Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol. 2008;141(4):545–548.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(12):3251–3258.
   PubMed Web of Science ®Google Scholar
• Li G, Wang S, Li N, et al. Proteasome inhibition with bortezomib induces apoptosis of long-lived plasma cells in steroid-resistant or relapsed immune thrombocytopaenia. Thromb Haemost. 2018;118(10):1752–1764.
   PubMed Web of Science ®Google Scholar
• Fadlallah J, Michel M, Crickx E, et al. Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia. Br J Haematol. 2019;187(1):124–128.
   PubMedGoogle Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar